Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Literature
1.
2.
Lindenblatt, et al. Solid pharmaceutical preparation containing levothyroxine. United States Patent Application Publication. Merck patent GMBH. US 2015/0231101 A1. 2015.
3.
ANSM. Direction des contrôles. 12/09/2017. Note de synthèse 17-A-033.
4.
Zamfirescu I, Carlson HE. Absorption of levothyroxine when coadministrated with various calcium formulations. Thyroid. 2011;21:483–6.CrossRef
5.
Poole RA, Kasper PT, Jiskoot W. Formation of amide- and imide-linked degradation products between the peptide drug oxytocin and citrate in citrate-buffered formulations. J Pharm Sci. 2011;100:3018–22.CrossRef
6.
Chumsae C, Zhou LL, Shen Y, Wohlgemuth J, Fung E, Burton R, et al. Discovery of a chemical modification by citric acid in a recombinant monoclonal antibody. Anal Chem. 2014;86:8932–6.CrossRef
Metadata
Title
Comment on: Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?
Author
Philippe Tréchot
Publication date
01-07-2019
Publisher
Springer International Publishing
Keyword
Levothyroxine
Published in
Clinical Pharmacokinetics / Issue 7/2019
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-019-00784-y

Other articles of this Issue 7/2019

Clinical Pharmacokinetics 7/2019 Go to the issue

Current Opinion

Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?

Letter to the Editor

Comment on: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”

Letter to the Editor

Authors’ Reply to Coste et al.: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”

Letter to the Editor

Authors’ Reply to Nicolas: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”

Original Research Article

Impact of Ethnicity-Specific Hepatic Microsomal Scaling Factor, Liver Weight, and Cytochrome P450 (CYP) 1A2 Content on Physiologically Based Prediction of CYP1A2-Mediated Pharmacokinetics in Young and Elderly Chinese Adults

Original Research Article

Physiologically Based Pharmacokinetic Modeling for Trimethoprim and Sulfamethoxazole in Children